Georgetown University Acquires 11,135 Shares of Danaher Corporation $DHR

Georgetown University raised its stake in Danaher Corporation (NYSE:DHR) by 30.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,069 shares of the conglomerate’s stock after purchasing an additional 11,135 shares during the period. Danaher makes up approximately 3.6% of Georgetown University’s holdings, making the stock its 11th biggest position. Georgetown University’s holdings in Danaher were worth $9,496,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in DHR. White Pine Capital LLC increased its stake in Danaher by 1.4% during the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock valued at $690,000 after acquiring an additional 49 shares during the period. Boyd Watterson Asset Management LLC OH grew its holdings in shares of Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock worth $499,000 after purchasing an additional 51 shares in the last quarter. Worth Financial Advisory Group LLC boosted its stake in Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after buying an additional 53 shares in the last quarter. 1834 Investment Advisors Co. raised its stake in shares of Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate’s stock valued at $342,000 after buying an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC lifted its holdings in shares of Danaher by 13.1% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock worth $92,000 after acquiring an additional 54 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on DHR. Robert W. Baird set a $247.00 price target on shares of Danaher in a research report on Wednesday, October 22nd. TD Cowen increased their target price on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Barclays boosted their price target on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft upped their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Activity

In related news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,248 shares of company stock valued at $6,609,663 over the last 90 days. 11.10% of the stock is owned by company insiders.

Danaher Trading Up 0.0%

DHR opened at $222.44 on Friday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The stock has a market capitalization of $157.12 billion, a PE ratio of 45.86, a PEG ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $207.83 and a two-hundred day moving average price of $201.76.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same period in the prior year, the firm earned $1.71 earnings per share. Danaher’s revenue was up 4.4% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s payout ratio is presently 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.